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The significance of R&D capabilities of China has become increasingly important as an emerging force in the
context of globalization of pharmaceutical research and development (R&D). While China has prospered in its R&D
capability in the past decade, how to integrate the rising pharmaceutical R&D capability of China into the global
development chain for innovative drugs remains challenging. For many multinational corporations and research
organizations overseas, their attempt to integrate China’s pharmaceutical R&D capabilities into their own is always
hindered by policy constraints and reluctance of local universities and pharmaceutical firms. In light of the situation,
contract research organizations (CROs) in China have made great innovation in value proposition, value chain and
value networking to be at a unique position to facilitate global and local R&D integration. Chinese CROs are now
being considered as the essentially important and highly versatile integrator of local R&D capability for global drug
discovery and innovation.
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China has prospered in its pharmaceutical research and
development (R&D) capability in the past decade [1-4]. The
Chinese government has invested massively to support
drug development in the country since the establishment of
“New Drug Creation and Development programme” in
2008 [5]. In 2012, the State Council issued “12th Five-Year
Development Plan for National Strategic Emerging In-
dustries” which strategically positioned biomedicine as
a key emerging industry [6]. The overwhelming support
has not only strengthened the research teams and upgraded
laboratory facilities in the local institutes, but also attracted
many Chinese scholars overseas to return and establish
their own technology firms in China. These efforts have
greatly contributed to the emerging pharmaceutical R&D
capabilities in China [7-9].
Despite the favorable conditions, challenges remain in
how to integrate the rising pharmaceutical R&D capability
of China into the global development chain for innovation
of new drugs [5]. Multi-national corporations (MNCs)* Correspondence: haohu@umac.mo
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unless otherwise stated.and research organizations overseas often find it difficult
to integrate China’s R&D capabilities into their own. For
instance, there are excessive government restrictions on
foreign organizations which intend to get or are already
involved in government-funded projects. On the other
hand, local academic researchers rely heavily on govern-
ment funding to sustain their work and focus primarily on
publishing academic papers to build up their academic
reputation. Cooperation with organizations overseas on
industrial drug discovery is not usually their top priority.
Moreover, local pharmaceutical companies can be highly
skeptical about the motivation of foreign pharamceutical
companies seeking R&D cooperation, which prevents
mutual consensus on establishing collaboration and al-
ways results in failures of joint venture and cooperation
projects.
In China, the contract research organization (CRO)
sector booms as they are expected to become a feasible
channel to facilitate the integration of local R&D cap-
abilities into global discovery and development [10-13].
Since 2008, we have started to investigate the Chinese
CROs by collecting data from multiple sources including
conducting field interviews with CRO managers and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and collecting archival documents of CROs from the com-
pany websites and public bibliographic databases. Until
the end of 2013, we collected substantial data about 66
leading Chinese CROs. In addition, we also interviewed
12 foreign pharmaceutical company managers, 10 local
university researchers and 8 policy makers. All the data
collected from the various sources indicated that Chinese
CROs were being considered as an essentially important
and highly versatile integrator of local R&D capability for
global drug discovery and innovation.
Evolution of Chinese CROs
The CRO industry in China began when Quintiles set up
its Hong Kong Office and MDS Pharma Service started
an investment company in Beijing in 1996. A key oppor-
tunity for the CROs to prosper appeared in 1998 when
the Chinese government implemented new drug registra-
tion regulations which mandated pharmaceutical compan-
ies to submit scientific evidence to prove safety and efficacy
of new drugs. In response to these regulatory requirements,
both local and global pharmaceutical companies were in
immediate need of agents that could provide R&D services.
Currently, there are about 300 CROs in China which
provide preclinical and clinical research services for MNCs,
local companies, as well as other R&D organizations such
as universities and academic institutes.
While China-based CROs only started in the clinical
trial arena, they entered the market of preclinical research
very soon with their significance increasing rapidly [10].
By 2012, there were more CROs focusing on preclinical
research service than those exclusively on clinical trials.
After the global financial crisis in 2008, there was even a
trend of outsourcing clinical trial services provided in
China. Under the influences of dynamic market fluctu-
ation and uncertainties in regulatory framework, industrial
consolidation of Chinese CROs happened dramatically
through mergers and acquisitions (M&A). Consequently,
many small Chinese CROs vanished, leaving a handful of
local leading CROs to become the key players such
asWuXi AppTec, Tigermed, and VenturePharm. In order
to compete against the global giant CROs such as Quin-
tiles, Covance, PPD, ICON, and Parexel, Chinese CROs
had to create their unique business models. Our study
clearly shows that in order to establish their standpoint,
China’s CROs had innovated their business model in three
aspects– value proposition, value chain and value network-
ing. By doing so, they had successfully evolved to facilitate
the integration of the nation’s R&D capabilities in response
to the global challenge.
From cost-saving to value-added proposition
Another distinctive observation revealed by our data is
that, unlike the traditional image of cost-saving serviceimposed by the notion of “made-in-China”, Chinese
CROs had changed their value proposition from just
cost-saving to value-added for clients. When the Chinese
CROs began their business at the beginning of 21st
century, most of them strived to survive by attracting
clients with their advantages of low human and material
cost without too much emphasis on the service quality.
However, the ruthless “red ocean” competition on price
and tough demands from high-end clients eventually
forced CROs with weak R&D and management capability
out of the market rapidly. The surviving CROs in China
then sought new value propositions through three main
aspects: i) they invested into technology improvement and
applied the most advanced biotechnology into their R&D
services; ii) they invested into R&D capacity building,
installed the most advanced laboratory instruments and
advanced laboratory facilities to ensure scale economy
and high efficiency; iii) they adopted global R&D standards
and guidelines into their practices to meet the inter-
national requirements including the Good Laboratory
Practice (GLP), Good Manufacturing Practice (GMP), and
Good Clinical Practice (GCP). All these efforts enabled
Chinese CROs to employ a new, systemic value propos-
ition which was recognized as an increasingly important
quality sought after by their clients.
There were many examples to demonstrate the import-
ant transition of Chinese CROs to from “cost-saving”
mindset to value-added proposition. The first one was
XBL-China, a CRO located in Nanjing City and founded
by returnee scholars from the United States [14]. This
CRO had innovative capabilities in drug metabolism and
bioanalytical method development and validation. In par-
ticular, it was equipped with world-class drug metabolism
and pharmacokinetic (DMPK) research capabilities, and
held a unique technology of using isotopes to trace the
pharmacokinetic features of candidate drugs in clinical
study. It also complied with the tGLP standards adopted
by both U.S. Food and Drug Administration (FDA) and
China Food and Drug Administration (CFDA) in order
to ensure the technological specification of the company
sufficiently meet the international quality standards,
and thereby guarantee efficiency and competency. Today,
this China-based CRO is among all the first choice for
both local and international clients which require isotopic
tracing technique.
Another successful example was Pharmaron which was
a preclinical CRO founded in 2003 by Chinese returnees
who were highly experienced researchers in pharma-
ceutical MNCs. In the beginning, this CRO operated in
accordance with the mission statement “to provide the
highest quality R&D services while helping our customers
advance their projects in a timely and cost-effective man-
ner” [15]. In addition to the strong pharmacochemistry cap-
ability, Pharmaron rapidly increased investment to acquire
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business scope from single business of chemical service
for drug R&D to a series of preclinical services across a
number of disciplines including chemistry, biology,
DMPK, pharmacology, toxicology and chemical develop-
ment. At present, Pharmaron is capable of conducting the
leading preclinical research that meets global standards.
Moreover, Pharmaron has developed an advanced infor-
mation system that provides clients with accurate and
timely traceability of their projects. Its core competence in
R&D capability and information management has secured
7 of the top 10 pharmaceutical MNCs as its long-term
clients.
Considering that the Chinese policy was determined to
fully support the sustainable development of traditional
Chinese medicine (TCM), some CROs such as Bionovo
chose to focus primarily on TCM-related contract service
[16]. Based on its accumulated capabilities in clinical trial
study of TCM, this CRO aimed its market share on Phase
I-IV clinical trial research for TCM. For this, Bionovo cre-
ated a series of clinical research practices and guidelines
to guide the practice of and ensure the quality of clinical
research of TCM. Moreover, it provided additional value
for its clients through promoting pharmaceutical econom-
ics of TCM which was also strongly encouraged by CFDA
and State Administration of Traditional Chinese Medicine
(SATCM) in recent years. Currently, it is able to provide
over 300 clinical research services across 20 therapeutic
areas, and is now expanding its business scope to consult-
ing services. This company has become a leading TCM
CRO taking up 60%-70% TCM clinical research market
share in China.
As demonstrated in the above examples, with the new
value propositions, the client scale and composition of
Chinese CROs have undergone huge transformation.
More and more local and global clients value and choose
the contract services provided by Chinese CROs and no
longer rely solely on the local academic organizations.
Both global and local clients are keen to offer more
technology-intensive and knowledge-oriented contracts
to Chinese CROs, which in turn help to boost the devel-
opment of R&D capabilities and profitability of Chinese
CROs accordingly.
Constructing a complete service chain
According to the data in our study, Chinese CROs were
able to carry out contract service that covers the entire
drug development value chain, ranging from early drug
discovery to post-market reassessment. The services
provided by Chinese CROs encompassed almost the
entire outsourcing market. At the same time, each of
these CROs had its own unique specialties and was
determined to reinvent its internal key business processes
to out-stand both local and overseas CROs.There are many preclinical CROs in China which are
of small scale facing throat-cut competition. In order to
survive, they need to have the appropriate R&D capability
to offer highly specialized services in the service chain that
no other CROs can match. One of the examples was
Tigermed which specialized in clinical trials, data man-
agement, biostatistics, regulatory affairs and medical
translation [17]. For cost reduction reasons, some global
CROs also relocated their clinical research business and
established multi-center clinical trial laboratory in
China. In this context, companies such as Tigermed set
up an in-house department for regulatory affairs to offer
customized regulatory services on pharmaceuticals, bio-
logical products, and medical devices. Tigermed was com-
mitted to accelerating medical product development with
cost efficiency and quality. While clinical trial planning,
management and implementation brought in the biggest
profit for Tigermed accounting for 58.6% of the total sales
in 2012, high gross margins were gained through both data
management (66.61%) and regulatory affairs (61.39%).
Tigermed was ready to expand and take a share of the
global market. Recently, Tigermed participated in an
international multi-center clinical research project run
by Lilly on an anti-diabetic drug.
As the overall Chinese CROs market thrives, some
large CROs take a step further to acquire an extended
value chain. WuXi AppTec, one of the largest CROs in
China, which used to operate only within the preclinical
experiment business has begun to provide “one-stop
service” with the full coverage from drug discovery to
clinical & regulatory [18]. To do this, WuXi AppTec
acquired AppTec (a famous American medical device
company) in 2008 and established integrated service.
On the contrary,VenturePharm, which started as a clinical
CRO, had successfully developed to provide preclinical re-
search services for big pharmaceutical companies.
Bridging network
As shown by the data in our study, Chinese CROs
enjoyed a great advantage of a unique integrated network
of local universities/academic institutes, hospitals and
domestic pharmaceutical firms. In any mature pharma-
ceutical sector around the world, pharmaceutical com-
panies (especially MNCs) were often the major platform
for drug R&D. In China, however, universities and research
institutes were the primary R&D forces and the local
pharmaceutical companies were still far from having
sufficient innovative capabilities. They received most of
the voluminous government financial investment and
were never short of expert resources. The sophisticated
connection of CROs with these university or research
institutes was one great advantage over foreign and local
pharmaceutical firms. Most CROs were in fact spin-offs
from universities and academic institutes or were founded
Table 1 Benefits and threats for foreign organization:
CRO, joint venture and cooperation
CRO Joint venture Cooperation
Benefits
Technology acquisition High High Low
Experimental efficiency High Low Low
Cost saving High Middle Low
Threats
Intellectual property risk Low High High
Coordination difficulty Low High High
Policy restriction Low High Middle
Shi et al. Globalization and Health 2014, 10:78 Page 4 of 6
http://www.globalizationandhealth.com/content/10/1/78by Chinese returnees who studied in the corresponding
university and still maintained good relationships with the
academic staff. Therefore, they could have access easily
to the well-equipped university laboratory and other
advanced facilities. This was also why Chinese CROs
were able to participate in many academic projects ini-
tiated by universities or researchers. In the same way,
Chinese CROs were also able to invite prestigious and
influential local researchers to provide professional
help to uplift their internal R&D competencies. For
instance, RunDo employed the executive president of
China nonprescription medicines association and an
academician of the Chinese Academy of Engineering as
its academic advisors [19].
In 2012, there were 1,431 hospitals in China, of which
420 had GCP certifications and a rich source of patients
enough for multiple clinical R&D studies. However,
foreign pharmaceutical firms always had huge difficulties
to get access to these hospitals and to initiate clinical re-
search simultaneously at different locations [20]. On the
contrary, Chinese CROs always had good relationships
with the local hospitals. For example, Tigermed devel-
oped a cooperation network that covered most high-end
hospitals to enable clinical research across China at the
same time. Through a similar network with hospitals,
many other Chinese CROs were also able to get involved
in innovative medical and drug research projects. Giant, a
clinical CRO in Beijing, was invited to participate a huge
mass data project to document and analyze medical
records from the most leading hospitals in China,
which was initiated by the Chinese Academy of Medical
Sciences [21].
Our study also showed that more and more local
pharmaceutical firms also preferred the service provided
by CROs in China. With the industrial policy and funding
support from government, some local pharmaceutical
firms also tried to develop their own R&D capabilities.
During the process, they might need to turn to CROs for
their professional help and even invite CROs to join their
innovative R&D project run or supported by government.
For example, Medicilon, a CRO founded by Chinese re-
turnees, participated in several innovative drug projects
run by local pharmaceutical companies and funded by the
Chinese government.
CROs in China were also found to be influential to the
implementation of price control on drugs initiated by
the Chinese government. The health system in China
was highly sophisticated and was exposed to significant
pricing and market access (P&MA) [22]. In the last
decade, the Chinese government continued to reinforce
price control on medicine at the national and provincial
level [23]. However, one of the major resistances in fact
originated at hospital level. In order to facilitate the listing
of their drugs products on the hospital formularymaintained by the in-house pharmacy, drug companies
needed to somehow get involved in the hospital listing
processes. To act as a bridge, CROs could also play a
role favorable to the drug companies and provide them
with important insights of government policy and the
implicit rules of pricing and market access of the cor-
responding hospital.
Integrator position of Chinese CROs
As discussed above, Chinese CROs had been trying to
evolve their business model to outshine themselves at the
international level. They successfully established a unique
position as a facilitator to integrate Chinese local R&D
capabilities through their collective and individual efforts
in three major aspects: (1) development of the in-house
R&D capabilities; (2) specialization and extension of their
technical roles throughout the entire value chain; and (3)
establishment of a competency network involving local
research units (universities, academic institutes, and
hospitals) and pharmaceutical firms. By employing their
growing R&D capabilities and their unique network
with the major players in the drug sector in China,
CROs were able to provide feasible and efficient means
for global players to enter China’s market and, at the same
time, integrate Chinese pharmaceutical R&D capabilities
into the global drug industry.
In order to optimize productivity and efficiency of a
research project, global pharmaceutical companies might
need to carefully design their strategies when acquiring
local R&D capabilities [24]. Taking into account the rising
pharmaceutical R&D capabilities in China, seeking help
from the Chinese CROs, which was often associated with
more benefits and less risks, was preferred by the global
companies over joint venture or cooperation of any form.
As shown in Table 1, participation of CRO in the business
could generate more benefits in terms of technology ac-
quisition, experimental efficiency and cost saving as CRO
was usually less constrained by complex operation proce-
dures and finance and technology exchange negotiation.
While joint venture could offer high level of technology
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antagonizing forces of complicated administration co-
ordination between joint venture partners which could
result in low experiment efficiency. Moreover, due to
loose cooperation agreement and heavy negotiation
burden, the benefits of technology acquisition, experi-
mental efficiency and cost saving through cooperation
agreement with local R&D organizations were usually
limited for foreign organizations.
In addition, joint venture and cooperation agreement
could also be hindered by concerns over possible intellec-
tual property leak, government regulation, and coordin-
ation cost. CROs could provide legal and business-based
mechanisms to protect foreign pharmaceutical companies
from these institutional threats [25]. This additional func-
tion of CROs was strongly encouraged and supported
by the Chinese government as part of the CRO industrial
development, unlike joint venture and cooperation agree-
ment which might have to undergo stringent government
review for approval in many cases. The risks of intellectual
property leak and possible coordination conflicts were
comparatively lower as the business contracts between
CROs and foreign organizations were usually clear and
specific.
Future perspectives
In summary, our study demonstrated that Chinese CROs
had evolved to be the most active component in the
Chinese pharmaceutical R&D arena. They had created
not only increasing business opportunities for themselves
but also generated extensive industrial impact for both
global and local pharmaceutical R&D.
As a service-oriented industry, CROs in China had
been dedicated to accommodate and fulfill their clients’
demands [26]. The Chinese CROs were considered as
the most efficient channel for foreign organizations to
obtain and use the emerging pharmaceutical innovation
capabilities in China. In particular for some MNCs, they
now realized the unique benefits of the services provided
by Chinese CROs and were keen on establishing closer re-
lationships with them. Some companies even set up Asian
research teams in China to implement and coordinate
their research strategies with Chinese CROs.
Simultaneously, Chinese CROs made great contributions
to the development of national pharmaceutical R&D
through their interactions with local academic units and
pharmaceutical companies. Our study also showed that
while Chinese CROs endeavored to improve their R&D
capabilities, they also acquired R&D management practices
through their business relationship with global clients.
This knowledge transfer did not stop within the CROs
but extended to the local universities and pharmaceut-
ical companies through their sophisticated linkage with
CROs. As a result, Chinese CROs reshaped the R&Dconfiguration of the national pharmaceutical sector and
exerted great impact on the overall pharmaceutical sec-
tor in China.
Chinese CROs were also found to be very prudent in
terms of avoiding conflicts between cost and service.
Some of them even changed the practice standards of
employing local resources in order to minimize the
risks. For example, Pharmaron no longer relied merely
on returnees from overseas and started to recruit local
researchers with Ph.D. degree who asked for less com-
pensation. It also established alliances with several fam-
ous laboratories of the local universities to get access to
their advanced laboratory instruments and facilities with
reasonably low cost. In addition, Pharmaron was able to
apply for government funding that was specifically set
for high-tech companies like CROs. By all these means,
Pharmaron and other CROs alike in China were able to
carefully maintain the service quality at a lower cost.
It was considered highly important by the CROs in
China to meet the high expectation on quality control
for both local and international clients. While purchasing
expensive laboratory instruments was relatively easy, how
to improve the internal management and operation
process to increase quality control remained a major
challenge for the Chinese CROs. In view of shortage of
appropriate local knowledge input, Chinese CROs had
to learn from the international CRO management and
practice guidelines adopted overseas. For example, XBL-
China was certified by the Association for Assessment
and Accreditation of Laboratory Animal Care (AAALAC)
to indicate its capability in quality control for animal ex-
periments. In addition, some CROs established separate
data management departments to ensure the accuracy
and integrity of experimental data.
Between 2001 and 2013, there were 19 policies and
regulations specific to CROs implemented by the Chinese
government. These policies and regulations directly
contributed to the development and industry integra-
tion of China-based CROs. For example, many pharma-
ceutical MNCs did not want to outsource their Phase I
to China and Chinese CROs could just conduct Phase
II-III clinical trials due to long administration process of
government and hospitals. The government, therefore,
dispatched the “Guiding Principle for Administration
on Phase I Clinical Trials on Drugs” in 2011 to better
regulate and streamline first-in-human clinical trials.
Moreover, the rising venture capital in China was paying
more attention to the CROs with advanced biotechnolo-
gies [27]. With a continuous emphasis on drug innovation
and global demand for innovative capabilities, Chinese
CROs are prepared to take up increasingly important role
as nexus of both external and internal pharmaceutical
R&D efforts, and play a critical role in the pharmaceutical
industry in China.
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